Comparing two treatments for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This study reviews data from patients with advanced stomach cancer who were treated with two different drug combinations. It aims to see which works better by comparing outcomes from those who received fruquintinib plus paclitaxel versus those who received ramucirumab plus paclitaxel.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or gastroesophageal junction cancer that is a type called adenocarcinoma.
- Your cancer is advanced or has spread to other parts of the body.
- You are able to care for yourself and are up and about more than half of the day (ECOG 0-1).
- You have already been treated with either fruquintinib plus paclitaxel or ramucirumab plus paclitaxel.
- You have enough medical history records for the researchers to compare patient groups.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (paclitaxel polymeric micelles and fruquintinib) for people with advanced stomach cancer that did not respond to first-line treatment. It aims to see if this combination can control the cancer with acceptable side effects.
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and FOLFOX chemotherapy) as the first treatment for advanced gastric (stomach) cancer. The goal is to see if this combination is safe and effective in shrinking tumors or slowing the cancer's growth.
This trial tests a combination of two oral drugs (paclitaxel and fruquintinib) for advanced stomach cancer that has already been treated with one round of chemotherapy. The goal is to see if this combination helps control the cancer better than other standard second-line treatments.
This study tests two different treatment options for advanced stomach or gastroesophageal junction cancer that has grown after earlier chemotherapy. One option combines a targeted therapy (ramucirumab) with a chemotherapy pill (trifluridine/tipiracil), and the other is a standard chemotherapy drug (paclitaxel). The goal is to see which approach works better for people whose cancer has progressed, with the hope of improving outcomes.
This study tests a combination of three drugs—fruquintinib, sintilimab, and XELOX chemo—for advanced stomach cancer. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
Hear when a new Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.